drugset / Trial / NCT04155918
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
RandomizedCrossoverOpen-labelTreatment
Summary
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
Timeline
- Start
- 2020-02-03
- Primary completion
- 2020-09-03
- Completion
- 2020-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR882 | Unknown | — | — |
| Subject | Allopurinol | Small molecule | — | — |
| Subject | Febuxostat | Small molecule | — | — |